Market closed
VolitionRX/$VNRX
VolitionRX shares are trading lower after the company reported its Q1 2025 financial results.
20 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About VolitionRX
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Ticker
$VNRX
Sector
Trading on
AMEX
Industry
Health Care Equipment & Supplies
Headquarters
Employees
85
ISIN
US9286611077
Website
VolitionRX Metrics
BasicAdvanced
$42M
-
-$0.27
-
-
Price and volume
Market cap
$42M
52-week high
$0.80
52-week low
$0.42
Average daily volume
279K
Financial strength
Current ratio
0.398
Quick ratio
0.337
Long term debt to equity
-21.472
Total debt to equity
-25.387
Interest coverage (TTM)
-67.15%
Management effectiveness
Return on assets (TTM)
-108.04%
Return on equity (TTM)
106.31%
Valuation
Price to revenue (TTM)
29.632
Price to book
-1.56
Price to tangible book (TTM)
-1.54
Price to free cash flow (TTM)
-1.735
Growth
Revenue change (TTM)
64.15%
Earnings per share change (TTM)
-40.16%
3-year revenue growth (CAGR)
94.17%
3-year earnings per share growth (CAGR)
-19.94%
What the Analysts think about VolitionRX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for VolitionRX stock.
VolitionRX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VolitionRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VolitionRX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for VolitionRX stock?
VolitionRX (VNRX) has a market cap of $42M as of May 17, 2025.
What is the P/E ratio for VolitionRX stock?
The price to earnings (P/E) ratio for VolitionRX (VNRX) stock is 0 as of May 17, 2025.
Does VolitionRX stock pay dividends?
No, VolitionRX (VNRX) stock does not pay dividends to its shareholders as of May 17, 2025.
When is the next VolitionRX dividend payment date?
VolitionRX (VNRX) stock does not pay dividends to its shareholders.
What is the beta indicator for VolitionRX?
VolitionRX (VNRX) does not currently have a Beta indicator.